Functional adenylyl cyclase inhibition in murine cardiomyocytes by 2′(3′)-O-(N-methylanthraniloyl)-guanosine 5′-[γ-thio] triphosphate

Journal of Pharmacology and Experimental Therapeutics

Volumn 321, Issue 2, 2007, Pages 608-615

  Rottlaender, Dennis ^a   Matthes, Jan ^a   Vatner, Stephen F ^b   Seifert, Roland ^c   Herzig, Stefan ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2'(3') O (N METHYLANTHRANILOYL) GUANOSINE 5' [GAMMA THIO]TRIPHOSPHATE; ADENYLATE CYCLASE; ADENYLATE CYCLASE INHIBITOR; CALCIUM CHANNEL L TYPE; ISOENZYME; ISOPRENALINE; UNCLASSIFIED DRUG;

ADRENERGIC SYSTEM; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CALCIUM CURRENT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; ENZYME INHIBITION; HEART MUSCLE CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADENYLATE CYCLASE; ANIMALS; ANTHRANILIC ACIDS; CALCIUM CHANNELS, L-TYPE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; GUANOSINE TRIPHOSPHATE; ISOPROTERENOL; MICE; MICE, INBRED C57BL; MYOCYTES, CARDIAC;

EID: 34247216741     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.118422     Document Type: Article

References (24)

1. 2-subunit. J Biol Chem 274:33851-33854.
2. Defer N, Best-Belpomme M, and Hanoune J (2000) Tissue specificity and physiological relevance of various isoforms of adenylyl cyclase. Am J Physiol 279:F400-F416.
3. q- overexpressing mice. Proc Natl Acad Sci USA 96:6400-6405.
4. 2-adrenergic receptors. Am J Physiol 279:H2456-H2463.
5. Engelhardt S, Hein L, Wiesmann F, and Lohse MJ (1999) Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice. Proc Natl Acad Sci USA 96:7059-7064.
6. 2-adrenoceptors. Proc Natl Acad Sci USA 100:14475-14480.
7. 2- adrenoceptor transgenic mice. Naunyn-Schmiedeberg's Arch Pharmacol 369:490-495.
8. Gao MH, Lai NC, Roth DM, Zhou J, Anzai T, Dalton N, and Hammond HK (1999) Adenylylcyclase increases responsiveness to catecholamine stimulation in transgenic mice. Circulation 99:1618-1622.
9. Gille A, Lushington GH, Mou T-C, Doughty MB, Johnson RA, and Seifert R (2004) Differential inhibition of adenylyl cyclase isoforms and soluble guanylyl cyclase by purine and pyrimidine nucleotides. J Biol Chem 279:19955-19969.
10. Gille A and Seifert R (2003) 2′(3′)-O-(N- Methylanthraniloyl)-substituted GTP analogs: a novel class of potent competitive adenylyl cyclase inhibitors. J Biol Chem 278:12672-12679.
11. Hanoune J and Defer N (2001) Regulation and role of adenylyl cyclase isoforms. Annu Rev Pharmacol Toxicol 41:145-174.
12. 2-adrenoceptor. Br J Pharmacol 133:73-82.
13. Ishikawa Y, Katsushika S, Chen L, Nalhon NJ, Kawabe J, and Homcy CJ (1992) Isolation and characterization of a novel cardiac adenylylcyclase cDNA. J Biol Chem 267:13553-13557.
14. Iwatsubo K, Minamisawa S, Tsunematsu T, Nakagome M, Toya Y, Tomlinson JE, Umemura S, Scarborough RM, Levy DE, and Ishikawa Y (2004) Direct inhibition of type 5 adenylyl cyclase prevents myocardial apoptosis without functional deterioration. J Biol Chem 279:40938-40945.
15. Kamp TJ and Hell JW (2000) Regulation of cardiac L-type calcium channels by protein kinase A and protein kinase C. Circ Res 87:1095-1102.
16. Laux WH, Pande P, Shoshani I, Gao J, Boudou-Vivet V, Gosselin G, and Johnson RA (2004) Pro-nucleotide inhibitors of adenylyl cyclases in intact cells. J Biol Chem 279:13317-13332.
17. Lohse MJ, Engelhardt S, and Eschenhagen T (2003) What is the role of β-adrenergic signaling in heart failure? Circ Res 93:896-906.
18. Mou T-C, Gille A, Fancy DA, Seifert R, and Sprang RA (2005) Structural basis for the inhibition of mammalian membrane adenylyl cyclase by 2′(3′)-O-(N-methylanthraniloyl)-guanosine 5-triphosphate. J Biol Chem 280:7253-7261.
19. Mou TC, Gille A, Suryanarayana S, Richter M, Seifert R, and Sprang SR (2006) Broad specificity of mammalian adenylyl cyclase for interaction with 2′,3′-substituted purine- and pyrimidine nucleotide inhibitors. Mol Pharmacol 70:878-886.
20. Okumura S, Kawabe J, Yatani A, Takagi G, Lee MC, Hong C, Liu J, Takagi I, Sadoshima J, Vatner DE, et al. (2003a) Type 5 adenylyl cyclase disruption alters not only sympathetic but also parasympathetic and calcium-mediated cardiac regulation. Circ Res 93:364-371.
21. Okumura S, Takagi G, Kawabe J, Yang G, Lee MC, Hong C, Liu J, Vatner DE, Sadoshima J, Vatner SF, et al. (2003b) Disruption of type 5 adenylyl cyclase gene preserves cardiac function against pressure overload. Proc Natl Acad Sci USA 100:9986-9990.
22. Tepe NM, Lorenz JN, Yatani A, Dash R, Krania EG, Dorn GW, and Liggett SB (1999) Altering the receptor-effector ratio by transgenic overexpression of type V adenylyl cyclase: enhanced basal catalytic activity and function without increased cardiomyocyte β-adrenergic signaling. Biochemistry 38:16706-16713.
23. 2+ channels. Cardiovasc Res 65:28-39.
24. 1- and β-adrenoceptor signaling in the heart. Trends Pharmacol Sci 27:330-337.